Literature DB >> 12394343

The I148T CFTR allele occurs on multiple haplotypes: a complex allele is associated with cystic fibrosis.

Elizabeth M Rohlfs1, Zhaoqing Zhou, Elaine A Sugarman, Ruth A Heim, Rhonda G Pace, Michael R Knowles, Lawrence M Silverman, Bernice A Allitto.   

Abstract

PURPOSE: To determine whether intragenic changes modulate the cystic fibrosis (CF) phenotype in individuals who are positive for the I148T allele.
METHODS: The genes from individuals who carried at least one copy of the I148T allele were analyzed for additional changes that may be acting as genetic modifiers.
RESULTS: Seven of eight individuals with a known or suspected diagnosis of CF who carried I148T in combination with a severe CF mutation also carried 3199del6. Eight apparently healthy adult individuals who were compound heterozygous for I148T and a severe CF mutation or homozygous for I148T did not carry the deletion ( = 0.0014). The I148T allele occurs on at least three haplotypes: an IVS-8 9T background, a 7T background, or a 9T + 3199del6 background. The 3199del6 allele was not identified in 386 non-CF chromosomes.
CONCLUSIONS: It is concluded that I148T occurs on at least three haplotypes and the complex allele I148T + 9T + 3199del6 is associated with a classic CF phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12394343     DOI: 10.1097/00125817-200209000-00001

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  23 in total

1.  Detection of an apparent homozygous 3120G>A cystic fibrosis mutation on a routine carrier screen.

Authors:  Denise LaMarche Heaney; Patrick Flume; Lauren Hamilton; Elaine Lyon; Daynna J Wolff
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

2.  Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations.

Authors:  Els Dequeker; Manfred Stuhrmann; Michael A Morris; Teresa Casals; Carlo Castellani; Mireille Claustres; Harry Cuppens; Marie des Georges; Claude Ferec; Milan Macek; Pier-Franco Pignatti; Hans Scheffer; Marianne Schwartz; Michal Witt; Martin Schwarz; Emmanuelle Girodon
Journal:  Eur J Hum Genet       Date:  2008-08-06       Impact factor: 4.246

3.  Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors.

Authors:  Elinor Langfelder-Schwind; Barbara Karczeski; Michelle N Strecker; Joy Redman; Elaine A Sugarman; Christina Zaleski; Trisha Brown; Steven Keiles; Amy Powers; Sumheda Ghate; Rebecca Darrah
Journal:  J Genet Couns       Date:  2013-09-07       Impact factor: 2.537

4.  The genetics and genomics of cystic fibrosis.

Authors:  N Sharma; G R Cutting
Journal:  J Cyst Fibros       Date:  2019-12-23       Impact factor: 5.482

5.  The genetics and neuropathology of neurodegenerative disorders: perspectives and implications for research and clinical practice.

Authors:  Vivianna M Van Deerlin
Journal:  Acta Neuropathol       Date:  2012-09       Impact factor: 17.088

Review 6.  Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.

Authors:  Ronald C Rubenstein
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

7.  Technical validation of a TM Biosciences Luminex-based multiplex assay for detecting the American College of Medical Genetics recommended cystic fibrosis mutation panel.

Authors:  Charles M Strom; Richard Janeszco; Franklin Quan; Sheng-biao Wang; Arlene Buller; Matthew McGinniss; Weimin Sun
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

8.  Complete gene scanning by temperature gradient capillary electrophoresis using the cystic fibrosis transmembrane conductance regulator gene as a model.

Authors:  Lan-Szu Chou; Friederike Gedge; Elaine Lyon
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

Review 9.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

10.  Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators.

Authors:  Antonella Caputo; Alexandre Hinzpeter; Emanuela Caci; Nicoletta Pedemonte; Nicole Arous; Marco Di Duca; Olga Zegarra-Moran; Pascale Fanen; Luis J V Galietta
Journal:  J Pharmacol Exp Ther       Date:  2009-06-02       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.